 |
 |
 |
 |
|
 |
Myskin™ is an active wound healing product for application to partial thickness burns, graft sites, diabetic foot ulcers and chronic wounds as part of a clinical wound management strategy.
Myskin™ is produced by CellTran limited, The Innovation Centre, 217 Portobello, Sheffield, UK. Myskin™ is produced according to the MHRA (UK) guidelines in our accredited aseptic production unit. The autologous sourcing of cells for myskin means that the product is produced on an individual need basis.
Myskin™ consists of a medical grade silicone sheet certified for time limited human implantation. This silicone sheet has a specially formulated surface coating of nanometre scale thickness, deposited by plasma polymerisation of acrylic acid. This coating allows the growth of a layer of proliferative, sub-confluent, autologous keratinocytes cultured under aseptic conditions in vitro.
Autologous keratinocytes are isolated from a small biopsy (tissue sample) from the patient. The dermal and epidermal layers are separated using an enzymatic process and keratinocytes are gently scraped from the dermal-epidermal interface.
Myskin™ is supplied as a 5cm diameter circular disc of surface area 19.6cm2. (Other formats may be supplied after consultation with CellTran.) Myskin™ is individually packaged on a sterile, buffered, serum-free mixture of Dulbecco's Modified Eagle’s medium (76%) and Hams F12 medium (23%) in an agar gel form.
Keratinocytes are co-cultured with irradiated murine cells during the production of myskin. The murine cells used in production of myskin have been tested for the presence of adventitious infections agents. This includes sterility testing for bacterial, fungal and mycoplasma contamination. Murine cells are not present in the final Myskin™ dressing product for application to wounds.
Click here to view our application animation.
Suitability of myskin™ | Clinical results | Myskin™ case studies | How to order myskin™ | Clinical use of myskin™ | Papers and publications | Professionals enquiry form